Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma
- PMID: 2581792
- DOI: 10.1002/eji.1830150518
Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma
Abstract
Interferons (IFN) are antiviral proteins that may be important in mediating cellular defenses against Epstein-Barr virus (EBV) infection. However, the means by which IFN-alpha, -beta and -gamma modify EBV infectivity are not clear. We have evaluated the effects of purified recombinant preparations of all three classes of IFN on EBV-induced B lymphocyte proliferation and Ig secretion. When added early after EBV infection, all three recombinant IFN reduced B cell outgrowth and Ig secretion. IFN-gamma exerted a 7-10-fold more potent antiviral effect than IFN-alpha or -beta. All three types of IFN act directly on B cells. Monocytes and natural killer cells are not necessary for the anti-EBV activity. Of the three recombinant IFN, only IFN-gamma reduced EBV-induced proliferation and Ig secretion when added 3-4 days after virus infection; IFN-alpha/beta were only effective up to 24 h. B lymphoblastoid lines already transformed by EBV are insensitive to the anti-proliferative actions of all three types of IFN. On the basis of these findings, we propose three phases of regulation during EBV infection. In the early phase, EBV-infected cells can be regulated by all IFN. Subsequently, there is an intermediate period where only IFN-gamma is capable of directly affecting EBV-induced B cell responses. In the third phase, B lymphocytes become insensitive to direct actions of all IFN and are now subject to regulation only by cytotoxic cells.
Similar articles
-
Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.J Immunol. 1986 May 15;136(10):3636-42. J Immunol. 1986. PMID: 3009608
-
Suppressive effect of human natural killer cells on Epstein-Barr virus-induced immunoglobulin synthesis.J Immunol. 1986 Sep 1;137(5):1462-8. J Immunol. 1986. PMID: 3018077
-
Effects of recombinant human interferons on rheumatoid arthritis B lymphocytes activated by Epstein-Barr virus.J Rheumatol. 1987 Feb;14(1):42-5. J Rheumatol. 1987. PMID: 3033238
-
Clinical and immunological considerations in Epstein-Barr virus-associated diseases.Scand J Infect Dis Suppl. 1996;100:72-82. Scand J Infect Dis Suppl. 1996. PMID: 8860357 Review.
-
Structure and effects of interferon-gamma.Oncology. 1985;42 Suppl 1:33-40. doi: 10.1159/000226082. Oncology. 1985. PMID: 3935992 Review.
Cited by
-
Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells.J Virol. 2012 Apr;86(8):4701-7. doi: 10.1128/JVI.06829-11. Epub 2012 Feb 15. J Virol. 2012. PMID: 22345482 Free PMC article.
-
Suppressor T cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis.J Clin Invest. 1987 Jan;79(1):7-14. doi: 10.1172/JCI112810. J Clin Invest. 1987. PMID: 3025263 Free PMC article.
-
Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo.J Clin Invest. 2004 Aug;114(4):542-50. doi: 10.1172/JCI22053. J Clin Invest. 2004. PMID: 15314691 Free PMC article.
-
The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells.J Virol. 2006 Dec;80(23):11638-50. doi: 10.1128/JVI.01570-06. Epub 2006 Sep 20. J Virol. 2006. PMID: 16987978 Free PMC article.
-
Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile.Blood Adv. 2019 Apr 9;3(7):1129-1144. doi: 10.1182/bloodadvances.2018025536. Blood Adv. 2019. PMID: 30952679 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials